Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster presentation 1

1225 - Assessment of Janus kinase family and Src family kinase signalling pathway involvement in epidermal growth factor-induced epithelial-mesenchymal transition in MDA-MB-468 breast cancer cells


19 Dec 2015


Poster presentation 1


Teneale Stewart


Annals of Oncology (2015) 26 (suppl_9): 1-7. 10.1093/annonc/mdv517


T.A. Stewart, I. Azimi, S.J. Roberts-Thomson, G.R. Monteith

Author affiliations

  • School Of Pharmacy, The University of Queensland, 4102 - Brisbane/AU


Abstract 1225


Epithelial-mesenchymal transition (EMT) is a process implicated in invasion and metastasis. MDA-MB-468 breast cancer cells undergo EMT in response to epidermal growth factor (EGF) stimulation with a significant up-regulation of mesenchymal markers (e.g vimentin) and a down-regulation of epithelial markers (e.g. E-cadherin). The present study evaluated the role of Janus kinase (JAK) family and Src family kinase (SFK) signalling in the regulation of EGF-induced EMT marker expression in MDA-MB-468 breast cancer cells.


To investigate the role of JAK and SFK signalling, serum-deprived (0.5% FBS) MDA-MB-468 breast cancer cells were pre-treated with either JAK Inhibitor I or the SFK inhibitor PP2 (0.1, 1 or 10 µM), respectively, for 1 h prior to stimulation with EGF (50 ng/mL) for 6 or 24 h. Real time RT-PCR was used to assess changes in mRNA levels of the EMT markers vimentin, Twist, Snail, N-cadherin and CD44/CD24. Immunoblotting was used to assess changes in STAT3 phosphorylation and vimentin protein expression. siRNA-mediated silencing of gene targets was performed using Dharmacon On-TARGETplus SMARTpool siRNA.


Both JAK Inhibitor I and PP2 (1 and 10 µM) significantly inhibited EGF-mediated STAT3 activation. SFK signalling did not appear to regulate downstream expression of any of the EMT markers assessed, while JAK inhibition significantly inhibited vimentin mRNA and protein induction, but not other EMT markers. Independent siRNA-mediated silencing of JAK family members failed to replicate the phenotype observed with JAK Inhibitor I treatment.


The JAK signalling pathway appears to regulate EGF-induced vimentin in MDA-MB-468 cells. Our results also suggest potential redundancy within the JAK family in the regulation of the EMT marker vimentin.

Clinical trial identification


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings